Adeoye Y. Olukotun
Known title: DirectorCIK: 0001242615
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TNXP Secures Second Medicare Agreement for TONMYA. Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.
Transaction History
| ARWR | ▼ Sell | Open Market | 2,000 | $174K | 8/18/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,090 | $206K | 12/19/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 6,083 | $414K | 12/19/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 827 | $57K | 12/19/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 7,819 | $0 | 12/16/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 959 | $20K | 1/23/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,850 | $57K | 12/27/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 16,733 | $385K | 12/18/2024 | View on chart |
| TNXP | ▼ Sell | Other | 1 | $2 | 6/10/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 14,987 | $381K | 12/15/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 11,350 | $371K | 3/3/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 7,867 | $0 | 1/10/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 6,400 | $0 | 1/7/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,916 | $125K | 1/3/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 244 | $16K | 1/3/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,890 | $121K | 1/3/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,250 | $143K | 9/13/2021 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,750 | $175K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.